European Medicines Agency; Release; 2012 Jun 22.
The EMA concludes that the benefits of Doribax (doripenem) continue to outweigh its risks but recommends updating the prescribing information to allow using a higher dose in certain patients with hospital-acquired pneumonia and to clarify the recommendations and warnings on the use of Doribax in different types of bacterial infection.
Weblink here
The EMA concludes that the benefits of Doribax (doripenem) continue to outweigh its risks but recommends updating the prescribing information to allow using a higher dose in certain patients with hospital-acquired pneumonia and to clarify the recommendations and warnings on the use of Doribax in different types of bacterial infection.
Weblink here